Date: 2013-09-17
Type of information: Initiation of the trial
phase: 3
Announcement: initiation of the trial
Company: Aragon Pharmaceuticals (USA - CA), now Johnson&Johnson (J&J) (USA - NJ)
Product: apalutamide (ARN-509, JNJ-56021927)
Action
mechanism: antiandrogen/androgen receptor blocker. Apalutamide is a non-steroidal antiandrogen that is under development for the treatment of prostate cancer. The compound is acting as a selective competitive antagonist of the androgen receptor.
Disease: prostate cancer
Therapeutic area: Cancer - Oncology
Country: Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Hungary, Israel, Japan, Republic of Korea, The Netherlands, New Zealand, Norway, Poland, Romania, Russian Federation, Slovakia, Spain, Sweden, Taiwan, UK USA,, Ireland
Trial
details: The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer. (NCT01946204 )
Latest
news: * On September 17, 2013, a Phase 3 trial sponsored by Aragon Pharmaceuticals was published on the NIH website ClinicalTrials.gov for apalutamide (ARN-509, JNJ-56021927) and is currently recruiting participants.
